BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34573408)

  • 1. A Curious Novel Combination of
    Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
    Martelli MP; Rossi R; Venanzi A; Meggendorfer M; Perriello VM; Martino G; Spinelli O; Ciurnelli R; Varasano E; Brunetti L; Ascani S; Quadalti C; Cardinali V; Mezzasoma F; Gionfriddo I; Milano F; Pacini R; Tabarrini A; Bigerna B; Albano F; Specchia G; Vetro C; Di Raimondo F; Annibali O; Avvisati G; Rambaldi A; Falzetti F; Tiacci E; Sportoletti P; Haferlach T; Haferlach C; Falini B
    Blood; 2021 Dec; 138(25):2696-2701. PubMed ID: 34343258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
    Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
    Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
    Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
    Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel NPM1 mutation in acute myeloid leukemia.
    Yao Y; Lin X; Wang C; Gu Y; Jin J; Zhu Y; Wang H
    Exp Hematol Oncol; 2023 Oct; 12(1):87. PubMed ID: 37794441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
    Falini B; Bolli N; Shan J; Martelli MP; Liso A; Pucciarini A; Bigerna B; Pasqualucci L; Mannucci R; Rosati R; Gorello P; Diverio D; Roti G; Tiacci E; Cazzaniga G; Biondi A; Schnittger S; Haferlach T; Hiddemann W; Martelli MF; Gu W; Mecucci C; Nicoletti I
    Blood; 2006 Jun; 107(11):4514-23. PubMed ID: 16455950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
    Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
    Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
    Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
    Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
    Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
    Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
    Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
    Bolli N; Nicoletti I; De Marco MF; Bigerna B; Pucciarini A; Mannucci R; Martelli MP; Liso A; Mecucci C; Fabbiano F; Martelli MF; Henderson BR; Falini B
    Cancer Res; 2007 Jul; 67(13):6230-7. PubMed ID: 17616680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
    Shi Y; Xue Y; Wang C; Yu L
    Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural consequences of nucleophosmin mutations in acute myeloid leukemia.
    Grummitt CG; Townsley FM; Johnson CM; Warren AJ; Bycroft M
    J Biol Chem; 2008 Aug; 283(34):23326-32. PubMed ID: 18511415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.
    Mukherjee H; Chan KP; Andresen V; Hanley ML; Gjertsen BT; Myers AG
    ACS Chem Biol; 2015 Mar; 10(3):855-63. PubMed ID: 25531824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Falini B
    Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of cytoplasmic nucleophosmin in formalin-fixed paraffin-embedded marrow trephine biopsies in acute myeloid leukaemia.
    Lit BM; Kwong YL; Wong KF
    J Clin Pathol; 2016 May; 69(5):409-14. PubMed ID: 26500335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.